For the quarter ending 2025-09-30, SLRX had $4,014,794 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -873,467 | -2,667,358 |
| Depreciation and amortization | 1,106 | 2,212 |
| Equity-based compensation expense | 22,846 | 56,689 |
| Prepaid expenses and other assets | 490,565 | 11,659 |
| Accounts payable | -310,839 | 337,971 |
| Accrued expenses and other current liabilities | 4,230 | 238,134 |
| Net cash used in operating activities | -1,646,689 | -2,044,011 |
| Short term promissory note | 200,000 | - |
| Net cash used in investing activities | -200,000 | - |
| Proceeds from issuance of equity securities, net | 5,861,483 | 626,235 |
| Payments on note payable | 0 | 221,866 |
| Net cash provided by (used in) provided by financing activities | 5,861,483 | 404,369 |
| Net decrease in cash and cash equivalents | 4,014,794 | -1,639,642 |
| Cash and cash equivalents at beginning of period | 2,434,528 | - |
| Cash and cash equivalents at end of period | 4,809,680 | - |
Salarius Pharmaceuticals, Inc. (SLRX)
Salarius Pharmaceuticals, Inc. (SLRX)